Division of Gastroenterology and Hepatology, Digestive Disease Center, Kitano Hospital, Osaka, Japan.
© Copyright 2016. Korean Association for the Study of Intestinal Diseases. All rights reserved.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Financial support: This work was supported by the Japan Society for the Promotion of Science (JSPS) Grants-in-aid for Scientific Research [25860532 to T.Y].
Conflict of interest: None.
Values are presented as n (%).
Categorical and continuous data were compared using a two-tailed Fisher exact test, Chi-squared test and Mann-Whitney U test.
M, male; F, female; 5-ASA, 5-aminosalicylic acid; AZA/6MP, Azathioprine/6-mercaptopurine; GMAA, granulocyte monocyte adsorption apheresis; TNF, tumor necrosis factor; N/A, not applicable.
Values are presented as n (%).
Categorical and continuous data were compared using a two-tailed Fisher exact test, Chi-squared test and Mann-Whitney U test.
M, male; F, female; 5-ASA, 5-aminosalicylic acid; AZA/6MP, Azathioprine/6-mercaptopurine; GMAA, granulocyte monocyte adsorption apheresis; TNF, tumor necrosis factor.
Variable | n=88 |
---|---|
Gender (M/F) | 45/43 |
Age at diagnosis (yr) (Median) | 34 (10–75) |
Extent of disease | |
Extensive colitis | 32 (36.4) |
Left-sided | 21 (23.9) |
Proctitis | 34 (38.6) |
Unclear | 1 (1.1) |
Endoscopic Mayo score | |
Mayo-0 | 43 (48.9) |
Mayo-1 | 45 (51.1) |
Maintenance therapy | |
5-ASA | 72 (81.8) |
AZA/6MP | 12 (13.6) |
GMAA | 1 (1.1) |
TNF-α antagonists | 6 (6.8) |
None | 8 (9.1) |
History of treatment with corticosteroid | 23 (26.1) |
Corticosteroid refractory | 4 (4.5) |
Corticosteroid dependent | 6 (6.8) |
Values are presented as n (%).
M, male; F, female; 5-ASA, 5-aminosalicylic acid; AZA/6MP, Azathioprine/6-mercaptopurine; GMAA, granulocyte monocyte adsorption apheresis; TNF, tumor necrosis factor.
Variable | Mayo-0 n=43 | Mayo-1 n=45 | P-value |
---|---|---|---|
Gender (M/F) | 23/20 | 22/23 | 0.666 |
Age at diagnosis (yr), median (range) | 34 (15–75) | 34 (10–71) | 0.333 |
Extent of disease | 0.361 | ||
Extensive colitis | 17 (39.5) | 15 (33.3) | |
Left-sided | 6 (14.0) | 15 (33.3) | |
Proctitis | 19 (44.2) | 15 (33.3) | |
Unclear | 1 (2.3) | 0 (0) | |
Maintenance therapy | |||
5-ASA | 35 (81.4) | 37 (82.2) | 0.860 |
AZA/6MP | 5 (11.6) | 7 (15.6) | 0.821 |
GMAA | 0 (0) | 1 (2.2) | N/A |
TNF-α antagonists | 1 (2.3) | 5 (11.1) | N/A |
None | 5 (11.6) | 3 (6.7) | N/A |
History of treatment with corticosteroid | 9 (20.9) | 14 (31.1) | 0.399 |
Corticosteroid refractory | 2 (4.7) | 2 (4.4) | N/A |
Corticosteroid dependent | 2 (4.7) | 4 (8.9) | N/A |
Values are presented as n (%).
Categorical and continuous data were compared using a two-tailed Fisher exact test, Chi-squared test and Mann-Whitney U test.
M, male; F, female; 5-ASA, 5-aminosalicylic acid; AZA/6MP, Azathioprine/6-mercaptopurine; GMAA, granulocyte monocyte adsorption apheresis; TNF, tumor necrosis factor; N/A, not applicable.
Variable | non-Relapse n=67 | Relapse n=21 | P-value |
---|---|---|---|
Gender (M/F) | 34/23 | 11/10 | 0.564 |
Age at diagnosis (yr), median (range) | 33 (10–75) | 35 (15–71) | 0.169 |
Extent of disease | 0.265 | ||
Extensive colitis | 21 (31.3) | 11 (52.4) | |
Left-sided | 15 (22.4) | 6 (28.6) | |
Proctitis | 30 (44.8) | 4 (19.0) | |
Unclear | 1 (1.5) | 0 (0) | |
Endoscopic Mayo score | 0.167 | ||
Mayo-0 | 36 (53.7) | 7 (33.3) | |
Mayo-1 | 31 (46.3) | 14 (66.7) | |
Maintenance therapy | |||
5-ASA | 53 (79.1) | 19 (90.5) | 0.338 |
AZA/6MP | 6 (9.0) | 6 (28.6) | 0.055 |
GMAA | 1 (1.5) | 0 (0) | 1.000 |
TNF-α antagonist | 3 (4.5) | 3 (14.3) | 0.145 |
None | 6 (9.0) | 2 (9.5) | 1.000 |
History of treatment with corticosteroid | 17 (25.4) | 6 (28.6) | 0.995 |
Corticosteroid refractory | 3 (4.5) | 1 (4.8) | 1.000 |
Corticosteroid dependent | 4 (6.0) | 2 (9.5) | 0.626 |
Values are presented as n (%).
Categorical and continuous data were compared using a two-tailed Fisher exact test, Chi-squared test and Mann-Whitney U test.
M, male; F, female; 5-ASA, 5-aminosalicylic acid; AZA/6MP, Azathioprine/6-mercaptopurine; GMAA, granulocyte monocyte adsorption apheresis; TNF, tumor necrosis factor.
Variable | HR | P-value | 95% CI | |
---|---|---|---|---|
Extensive colitis | 1.647 | 0.343 | 0.587 | 4.621 |
Mayo-1 | 1.687 | 0.279 | 0.654 | 4.353 |
Immunomodulator use | 6.134 | 0.035 | 1.134 | 33.17 |
HR, hazard ratio.
Values are presented as n (%). M, male; F, female; 5-ASA, 5-aminosalicylic acid; AZA/6MP, Azathioprine/6-mercaptopurine; GMAA, granulocyte monocyte adsorption apheresis; TNF, tumor necrosis factor.
Values are presented as n (%). Categorical and continuous data were compared using a two-tailed Fisher exact test, Chi-squared test and Mann-Whitney M, male; F, female; 5-ASA, 5-aminosalicylic acid; AZA/6MP, Azathioprine/6-mercaptopurine; GMAA, granulocyte monocyte adsorption apheresis; TNF, tumor necrosis factor; N/A, not applicable.
Values are presented as n (%). Categorical and continuous data were compared using a two-tailed Fisher exact test, Chi-squared test and Mann-Whitney M, male; F, female; 5-ASA, 5-aminosalicylic acid; AZA/6MP, Azathioprine/6-mercaptopurine; GMAA, granulocyte monocyte adsorption apheresis; TNF, tumor necrosis factor.
HR, hazard ratio.